Raptor Pharmaceutical Licenses Intellectual Property for Rett Syndrome From French Research Institutes
May 07, 2013 07:00 ET
|
Raptor Pharmaceutical Inc
Raptor Expands its Cysteamine Rights for the Treatment of Neurologic Disorders
License Grants Raptor Exclusive Worldwide Rights to the Use of Cysteamine and Related Compounds in the Treatment of...
Raptor Pharmaceutical Corp. Reports Financial Results for the Transition Period From September 1, 2012 to December 31, 2012
March 14, 2013 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., March 14, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today reported financial results for its four month transition period from...
Raptor Pharmaceutical Corp. to Present at the Cowen and Company 33rd Annual Health Care Conference
February 26, 2013 17:15 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Feb. 26, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), today announced that Julie Anne Smith, executive vice president, strategy and chief operating officer of...
Raptor Pharmaceutical Corp. to Present at Upcoming Investor Conferences
February 05, 2013 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), today announced that the company's management will present at two upcoming investor conferences in February....
Raptor Pharmaceutical Corp. Reports First Quarter Fiscal Year 2013 Financial Results
January 09, 2013 16:00 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Jan. 9, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today reported financial results for its first fiscal quarter ended November 30,...
Raptor Pharmaceutical Corp. Provides Update on PROCYSBI(TM) NDA Review
December 21, 2012 16:29 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Dec. 21, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that the U.S. Food and Drug Administration ("FDA") will require...
Raptor Pharmaceutical Corp. Signs $50 Million Loan Agreement With HealthCare Royalty Partners
December 20, 2012 09:00 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Dec. 20, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that it has signed a $50 million loan agreement with HealthCare...
Raptor Pharmaceutical Corp. Reports Fourth Quarter and Fiscal Year 2012 Financial Results
November 14, 2012 06:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Nov. 14, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today reported financial results for its fourth quarter and fiscal year ended...
Raptor Pharmaceutical Corp. to Present at the Lazard Capital Markets 9th Annual Healthcare Conference 2012
November 09, 2012 14:10 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Nov. 9, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that Julie Anne Smith, Executive Vice President, Strategy and...
Raptor Pharmaceutical Corp. Announces Positive Data on RP103 Extension Study Presented at Kidney Week 2012
November 05, 2012 06:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced that Craig B. Langman, M.D., Head of Kidney Diseases, and the Isaac A....